Multicancer Screening Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031F

Hospitals is the fastest growing sector, North America is the largest market

The global multicancer screening market is anticipated to expand significantly, from USD 1.73 billion in 2025 to USD 4.06 billion by 2031, demonstrating a compound annual growth rate of 15.28%. This growth is driven by multicancer early detection (MCED) products, which are diagnostic tools employing liquid biopsy technology to identify biological signals, like circulating tumor DNA, from various types of malignancies using a single blood sample. Key factors propelling this market include the increasing global incidence of cancer and a broader shift towards preventive healthcare that emphasizes non-invasive diagnostic methods.

These assays offer a distinct advantage by detecting aggressive cancers that currently lack established screening protocols, thereby offering a valuable solution for healthcare systems aiming to reduce late-stage diagnoses.The urgent demand for these tools is underscored by projections such as the American Cancer Society's estimate of approximately 2,041,910 new cancer cases in the United States in 2025. However, a significant obstacle for the market is securing reimbursement, as insurers typically postpone coverage decisions until definitive longitudinal data proves a reduction in mortality rates.

Market Drivers

The global multicancer screening market is being fundamentally reshaped by advancements in liquid biopsy and next-generation sequencing, which enable the precise detection of circulating tumor DNA and methylation patterns indicative of early-stage cancers. These technological enhancements facilitate the simultaneous identification of signals from multiple cancer types from a single blood draw, thereby significantly broadening diagnostic capabilities beyond conventional single-indication screenings. The clinical effectiveness of these sophisticated platforms is increasingly validated by robust performance data, which is crucial for their widespread adoption.

For example, a GRAIL study in October 2025, the 'PATHFINDER 2 Study Update', showed that incorporating the Galleri test into standard-of-care screenings led to over a seven-fold increase in cancer detection compared to standard screening alone, highlighting liquid biopsy's efficacy in addressing the critical need for tools to identify lethal cancers currently lacking standard screening protocols.Market growth is further accelerated by strategic collaborations and partnerships within the biotechnology sector, where diagnostic companies are partnering with technology and pharmaceutical leaders to secure funding and enhance commercial scalability.

These alliances provide essential capital and operational support, enabling companies to navigate complex regulatory processes and expand the distribution of multicancer early detection (MCED) tests. An illustrative instance of this trend is Samsung's $110 million equity investment in GRAIL in November 2025, as reported in GRAIL's 'Third Quarter 2025 Financial Results', aimed at supporting development and commercialization. The substantial financial capacity of the wider screening sector, evidenced by Exact Sciences' $851 million revenue in the third quarter of 2025, also underscores the significant resources available for these advancements and the strong commercial foundation for future multi-cancer solutions.

Market Challenges

A significant barrier to the commercial scalability of the global multicancer screening market is the strict requirement for longitudinal mortality data to secure reimbursement. Insurers typically defer coverage decisions until the clinical utility of multicancer early detection (MCED) tests is conclusively demonstrated, which means these tests largely remain out-of-pocket expenses for most patients. This lack of payer support confines the market to a specialized segment of affluent individuals, thereby hindering the widespread adoption necessary for revenue growth and achieving economies of scale.

Without a clear path to standard insurance coverage, these diagnostic tools cannot evolve from optional luxury items into fundamental elements of population health management.The adverse effects of this financial hurdle are exacerbated by existing challenges in maintaining patient adherence to screening protocols. For instance, the Prevent Cancer Foundation reported that in 2025, only 51% of U.S. adults completed their routine cancer screenings, representing a notable decrease from the prior year. This statistic underscores the already fragile nature of patient engagement, even for well-established and frequently covered procedures. Consequently, the absence of reimbursement for novel, expensive MCED assays will almost certainly lead to minimal adoption rates among the general populace, directly impeding the market's progression.

Market Trends

The market is being revolutionized by the integration of Artificial Intelligence and Deep Learning for biomarker discovery, which significantly boosts the sensitivity of assays for early-stage malignancies. These sophisticated algorithmic platforms go beyond traditional single-variant detection by analyzing intricate fragmentation patterns and methylation signatures to precisely differentiate authentic tumor-derived signals from background somatic noise. This technological advancement is crucial for detecting cancers with low shedding rates, which frequently elude standard liquid biopsy methods.

For instance, Harbinger Health reported in May 2025 that its AI-enabled platform achieved 25.8% sensitivity for early-stage cancers at 98.3% specificity within a high-risk population, confirming machine learning's capacity to enhance detection accuracy.A key commercial shift involves integrating multicancer screening into corporate wellness programs, a strategy designed to circumvent existing reimbursement challenges.

Diagnostic developers are increasingly bypassing conventional payer channels by directly collaborating with self-insured employers and life insurance providers, positioning MCED tests as valuable health benefits for employee retention and preventive care. This business-to-business approach generates immediate revenue streams and accumulates real-world evidence while comprehensive insurance coverage policies are still being developed. The financial effectiveness of this adoption channel is clear, as GRAIL reported in November 2025 that Galleri revenue grew 29% year-over-year to $32.8 million, primarily driven by expanded commercial partnerships and employer adoption.

Key Market Players

• Agilent Technologies, Inc.
• Atara Biotherapeutics, Inc.
• Burning Rock Biotech Limited
• Exact Sciences Corporation
• F. Hoffmann-La Roche Ltd.
• Fulgent Genetics, Inc.
• Genecast Biotechnology Co., Ltd.
• Guardant Health, Inc.
• Illumina, Inc.
• Konica Minolta, Inc.

Report Scope

In this report, the Global Multicancer Screening Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Multicancer Screening Market, by Test Type:

• Laboratory Developed Tests (LDTs)
• In-Vitro Diagnostics (IVDs)

Multicancer Screening Market, by Technology:

• Next-Generation Sequencing (NGS)
• Polymerase Chain Reaction (PCR)
• Immunohistochemistry (IHC)
• Fluorescence In-Situ Hybridization (FISH)
• Others

Multicancer Screening Market, by Sample:

• Tissue
• Blood
• Saliva and Buccal Swab
• Others

Multicancer Screening Market, by Method:

• DNA
• RNA
• Proteins

Multicancer Screening Market, by Cancer Type:

• Breast and Gynecologic
• Gastrointestinal
• Endocrine
• Genitourinary
• Skin
• Brain/Nervous System
• Sarcoma
• Hematological Malignancies
• Lung
• Head and Neck
• Other Cancer Types

Multicancer Screening Market, by Application:

• Clinical
• Research

Multicancer Screening Market, by End User:

• Hospitals
• Diagnostic and Clinical Laboratories
• Academic Research Institutions
• Others

Multicancer Screening Market, by Region:

• North America
• Europe
• Asia Pacific
• South America
• Middle East & Africa

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Multicancer Screening Market.

Available Customizations:

With the given market data, the publisher offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

This product will be delivered within 1-3 business days.